Maxine Joly-Chevrier
Crédit : Association médicale canadienne
Les personnes n’ont pas constaté de différences cliniquement significatives dans leur arthrite psoriasique (AP) entre les conditions climatiques estivales et hivernales, bien que des différences aient été observées.1
Joly-Chevrier et ses collègues ont comparé les données horaires sur la température, l’humidité relative et la pression entre 2015 et 2020 de Montréal (Environnement Canada) avec l’activité de la maladie (DA) et les résultats rapportés par les patients (PRO) des patients atteints de PsA inscrits au registre des patients RHUMADATA. Ils ont comparé la différence de DA moyenne entre l’hiver et l’été et ont calculé les coefficients de corrélation de Pearson entre le profil clinique et les mesures météorologiques.
Les chercheurs ont recueilli 2 665 PRO auprès d’un total de 858 patients atteints de PsA. Parmi les données DA/PRO recueillies, seuls les scores de l’indice d’activité clinique de la maladie (CDAI) (moyenne, 8,2 ; écart type [SD]7,8) et les scores de l’indice simplifié d’activité de la maladie (SDAI) (moyenne, 8,6 ; ET, 7,6) étaient plus faibles en hiver qu’en été (CDAI [mean, 8.8; SD, 7.9; P = .001]SDAI [mean, 9.5; SD, 8.0; P 1
Joly-Chevrier and colleagues found that summer revealed positive correlations between humidity and scores on patient global assessment (PtGA), fatigue, pain, c- reactive protein (CRP), bath ankylosing spondylitis disease activity index (BASDAI), and bath ankylosing spondylitis functional index (BASFI) and negative correlations between temperature and health assessment questionnaire disability index (HAQ-DI) scores. Winter had positive correlations between temperature, fatigue, and pain.
However, the investigators found significant correlations between gender, age, and disease duration, and optimal regression models derived based on Akaike’s Information Criteria suggested that weather may account for less than 1% of the variation in PROs, which may reflect disease activity.
Other recent research into PsA found that patinets did not have notable differences in clinical parameters before initiating biologic (b) and targeted synthetic (ts) disease modifying anti-rheumatic drugs (DMARDs) mono or methotrexate (MTX)-combination therapy and treatment decisions were driven by subjective tolerability of MTX.2
The combination group had a mean drug retention time of 15.2 months and the monotherapy group had a mean drug retention time of 14.4 months. At 6 months, 48% of the combination group and 66% of the monotherapy group were still on their original treatment; at 12 months, these proportions were 48% and 67%, respectively. Adjusted treatment retention rates were found to be similar between groups (P = .04).2
REFERENCES
- Joly-Chevrier M, Coupal L, Sauvageau LC, Movahedi M, Choquette D. A Real-World Analysis on Weather Variation Disease Activity and Patient Reported Outcomes in Psoriatic Arthritis. J Rheumatol. Published online September 15, 2024. doi:10.3899/jrheum.2024-0520
- Regierer AC, Kiefer D, Schett D, et al. No difference in clinical parameters and drug retention in PsA patients receiving b/tsDMARD monotherapy versus combination with methotrexate: data from the RABBIT-SpA registry. RMD Open 2024;10:e004389. doi: 10.1136/rmdopen-2024-004389
2024-09-22 21:06:58
1727028729
#météo #quun #impact #limité #sur #les #symptômes #larthrite #psoriasique
